Addex, Merck Ink $702M Deal for Schizophrenia Compound Jan. 9, 2008 By Cormac Sheridan Merck & Co. Inc. demonstrated its liking for Addex Pharmaceuticals AG's approach to modulating glutamate receptors by entering a second deal with the Swiss firm in consecutive months. (BioWorld International)Read More
Report from Europe: French certification lab eyes American orthopedic makers Jan. 9, 2008 By John Brosky
RSS